Loading…
Fate Therapeutics, Inc. is projected to rise to $4.54 by 2027, a +46% move from its current price of $3.10. FATE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $2.93 | $3.10 | $3.29 | +0.13% |
| Jul 13 | $2.86 | $3.11 | $3.37 | +0.26% |
| Jul 14 | $2.81 | $3.11 | $3.44 | +0.40% |
| Jul 15 | $2.78 | $3.12 | $3.50 | +0.53% |
| Jul 16 | $2.74 | $3.12 | $3.55 | +0.66% |
| Jul 17 | $2.71 | $3.12 | $3.60 | +0.79% |
| Jul 18 | $2.68 | $3.13 | $3.65 | +0.93% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.68 | $3.13 | $3.65 | +0.93% |
| Week 2 | $2.54 | $3.16 | $3.92 | +1.86% |
| Week 3 | $2.44 | $3.19 | $4.16 | +2.81% |
| Week 4 | $2.37 | $3.22 | $4.37 | +3.76% |
| Week 5 | $2.30 | $3.25 | $4.58 | +4.73% |
| Week 6 | $2.25 | $3.28 | $4.77 | +5.70% |
| Week 7 | $2.20 | $3.31 | $4.96 | +6.68% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company is headquartered in San Diego, California and was incorporated in 2007.
It pursues CAR T-cell and CAR-targeted NK and T-cell programs, including FT836 in preclinical stages for multiple tumor types, FT522 for B-cell Lymphoma and autoimmunity, and CAR T-cell programs such as FT819, FT839, and FT825. Fate also has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd.
for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for solid tumors.
Fate Therapeutics trades as FATE, currently priced at $3.02 with a market cap of $352.01M and a market-rank position of 3384. The stock’s price action is accompanied by bullish sentiment and a 30-day technical range that reflects both upside potential and risk. The current price sits within a broader forecast that projects meaningful upside over the coming years, with multi-year targets showing substantial growth.
A major floor 65.8% below — a decisive break under it would weaken the trend.
The nearest floor, 39.7% below — buyers have tended to step in here.
Price is pressing into resistance (0.3% away) — a breakout level to watch.
A major ceiling 26.9% above — clearing it would confirm fresh momentum.
Key FATE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FATE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.03 | Buy | $3.01 | Buy |
| MA 10 | $2.83 | Buy | $2.83 | Buy |
| MA 20 | $2.43 | Buy | $2.59 | Buy |
| MA 50 | $2.23 | Buy | $2.23 | Buy |
| MA 100 | $1.76 | Buy | $1.91 | Buy |
| MA 200 | $1.47 | Buy | $1.67 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 68.53 | Neutral |
| Stoch RSI (14) | 91.73 | Sell |
| CCI (20) | 102.58 | Buy |
| Williams %R (14) | -0.81 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | 43.52 | Buy |
| Bollinger %B (20,2) | 0.86 | Neutral |
| Stochastic %K (14) | 99.19 | Sell |
| TRIX (15) | 1.21 | Buy |
| Awesome (5,34) | 0.67 | Buy |
| Ultimate (7,14,28) | 72.07 | Sell |
| Momentum (10) | 1.23 | Buy |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 3.11 | Sell |
| ADX (14) | 23.06 | Buy |
| ATR (14) | 0.13 | Info |
Near-term technicals show bullish sentiment with an RSI of 70 and the price trading above the SMA50 of $2.02 while SMA200 sits at $1.40. The stock has a defined support level at $1.84 and a resistance at $3.02. Over the last 30 days, the price has ranged from $1.94 to $4.71, indicating fresh volatility and potential momentum shifts.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.99 | $3.10 | $4.88 | 0% | Neutral | |
| $3.29 | $4.54 | $6.76 | +46% | Bullish | |
| $3.48 | $5.09 | $8.09 | +64% | Bullish | |
| $3.29 | $5.07 | $8.46 | +64% | Bullish | |
| $3.52 | $5.70 | $9.89 | +84% | Bullish | |
| $3.75 | $6.35 | $11.41 | +105% | Bullish | |
| $5.36 | $9.45 | $17.51 | +205% | Bullish | |
| $6.74 | $12.37 | $23.56 | +299% | Bullish | |
| $5.67 | $10.83 | $21.14 | +249% | Bullish | |
| $5.62 | $11.16 | $22.28 | +260% | Bullish | |
| $9.26 | $20.57 | $45.15 | +563% | Bullish | |
| $19.85 | $44.11 | $101.45 | +13.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.99 | $3.10 | $3.76 | +0.00% |
| August 2026 | $2.65 | $3.21 | $4.05 | +3.42% |
| September 2026 | $2.85 | $3.50 | $4.51 | +9.06% |
| October 2026 | $2.83 | $3.53 | $4.62 | +0.84% |
| November 2026 | $2.73 | $3.43 | $4.56 | -2.73% |
| December 2026 | $2.85 | $3.62 | $4.88 | +5.49% |
Click any year to see its month-by-month FATE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, FATE is projected to trade between $0.99 and $4.88, averaging $3.10 — a potential gain of 0% from today's $3.10. A consolidation phase looks the most probable path here.
Fate Therapeutics, Inc.'s 2027 outlook centres on $4.54, within a $3.29 to $6.76 range. That is up +46% on the projected 2026 average. That marks a +46% change versus current levels. Momentum favours further upside here.
By 2028, FATE could reach as high as $8.09, with a base case around $5.09 and support toward $3.48 — roughly +64% from $3.10. Buyers look set to stay in control over this stretch.
Expect FATE to range from $3.29 to $8.46 through 2029. The $5.07 average target implies a +64% move from current prices. That is 0% versus the projected 2028 average. Momentum favours further upside here.
The FATE price prediction for 2030 points to an average of $5.70 (low $3.52, high $9.89) — a potential gain of +84% on today's $3.10. Buyers look set to stay in control over this stretch.
In 2031, FATE is projected to trade between $3.75 and $11.41, averaging $6.35 — a potential gain of +105% from today's $3.10. That is up +11% on the projected 2030 average. Momentum favours further upside here.
Fate Therapeutics, Inc.'s 2032 outlook centres on $9.45, within a $5.36 to $17.51 range. That is up +49% on the projected 2031 average. That marks a +205% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, FATE could reach as high as $23.56, with a base case around $12.37 and support toward $6.74 — roughly +299% from $3.10. Momentum favours further upside here.
Expect FATE to range from $5.67 to $21.14 through 2034. The $10.83 average target implies a +249% move from current prices. That is -12% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The FATE price prediction for 2035 points to an average of $11.16 (low $5.62, high $22.28) — a potential gain of +260% on today's $3.10. Momentum favours further upside here.
In 2040, FATE is projected to trade between $9.26 and $45.15, averaging $20.57 — a potential gain of +563% from today's $3.10. That is up +84% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Fate Therapeutics, Inc.'s 2050 outlook centres on $44.11, within a $19.85 to $101.45 range. That is up +114% on the projected 2040 average. That marks a +13.2x change versus current levels. Momentum favours further upside here.
Investing $1,000 in FATE today (≈ 322.580645 FATE) could be worth
$14,229.03
+$13,229.03 (+1323%) by 2050 · US Dollar
Based on the average projected FATE price of $44.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FATEwould be worth at today's price.
$1,000 invested in FATE on Jul 10, 2025 (≈ 862.06899 FATE) would be worth
$2,672.41
+$1,672.41 (+167.2%) today · 2.67× · US Dollar
Based on a FATE entry price of $1.16 vs. today's $3.1.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.92 | $1,061.64 | +6.2% |
| 1 month ago | $1.87 | $1,657.75 | +65.8% |
| 3 months ago | $1.24 | $2,500 | +150.0% |
| 6 months ago | $1.07 | $2,897.2 | +189.7% |
| 1 year ago | $1.16 | $2,672.41 | +167.2% |
| All time (5.0y) ago | $85.92 | $36.08 | -96.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FATE forecast.
Our base-case forecast reaches $6.20 around 2031.
Implied market cap at $6.20: $722.67M
The multi-year forecast presents a progression from a 2026 avg of $3.02 toward higher prices, with 2027 avg $4.38 and 2030 avg $5.39, accompanied by rising ROI figures (45.1% in 2027, 78.5% in 2030, and up to 1329.1% by 2050). The forecast shows continued bullish sentiment beyond 2030, with 2032 avg $9.37, 2033 avg $11.80, 2040 avg $19.85 and 2050 avg $43.16, signaling substantial potential upside over the long term. These are estimates, not guarantees, and involve notable uncertainty and market risk.
Tap a question to reveal the answer.
Avg $5.39 with a min of $3.33 and a max of $9.36; ROI 78.5%; sentiment is BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising average prices through 2035, 2040 and 2050, but these are estimates and not guarantees.
Yes. The forecast shows 2032 avg $9.37 and 2033 avg $11.80 with a max of $22.48, indicating the possibility of exceeding $10 in the early 2030s.
Current price is $3.02 and market cap is $352.01M.
The 30-day range is from $1.94 to $4.71.
Fate Therapeutics, Inc. Community Discussion
0Share your Fate Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.